Chemical reversal of the RNA gain of function in myotonic dystrophy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 44, 2009, Pages 18433-18434

  Cooper, Thomas A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYOTONIC DYSTROPHY PROTEIN KINASE; PENTAMIDINE; RNA; RNA BINDING PROTEIN;

ALTERNATIVE RNA SPLICING; GENE EXPRESSION; GENE INTERACTION; GENE MUTATION; HUMAN; MYOTONIC DYSTROPHY; NONHUMAN; NOTE; PATHOGENESIS; PRIORITY JOURNAL;

ALTERNATIVE SPLICING; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MYOTONIC DYSTROPHY; PENTAMIDINE; RNA PRECURSORS; RNA-BINDING PROTEINS; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 73249146284     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0910643106     Document Type: Note

References (18)

1. Orr HT, Zoghbi HY (2007) Trinucleotide repeat disorders. Annu Rev Neurosci 30:575-621.
2. Wheeler TM, Thornton CA (2007) Myotonic dystrophy: RNA-mediated muscle disease. Curr Opin Neurol 20:572-576.
3. Warf MB, Nakamori M, Matthys CM, Thornton CA, Berglund JA (2009) Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proc Natl Acad Sci USA 106:18551-18556.
4. Harper PS (2001) Myotonic Dystrophy (Saunders, London), 3rd Ed.
5. Dansithong W, Paul S, Comai L, Reddy S (2005) MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1. J Biol Chem 280:5773-5780.
6. Miller JW, et al. (2000) Recruitment of human muscleblind proteins to(CUG)nexpansions associated withmyotonic dystrophy. EMBO J 19:4439-4448.
7. Kuyumcu-Martinez MN, Wang GS, Cooper TA (2007) Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell 28:68-78.
8. Cooper TA, Wan L, Dreyfuss G (2009) RNA and disease. Cell 136:777-793.
9. Mahadevan MS, et al. (2006) Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy. Nat Genet 38:1066-1070.
10. Arambula JF, Ramisetty SR, BarangerAM,ZimmermanSC (2009) A simple ligand that selectively targets CUG trinucleotide repeats and inhibits MBNL protein binding. Proc Natl Acad Sci USA 106:16068-16073.
11. Gareiss PC, et al. (2008) Dynamic combinatorial selection of molecules capable of inhibiting the (CUG) repeat RNA-MBNL1 interaction in vitro: Discovery of lead compounds targeting myotonic dystrophy (DM1). J Am Chem Soc 130:16254-16261.
12. Lee MM,Pushechnikov A, Disney MD (2009) Rational and modular design of potent ligands targeting theRNAthat causes myotonic dystrophy 2. ACS Chem Biol 4:345-355.
13. Pushechnikov A, et al. (2009) Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3. J Am Chem Soc 131:9767-9779.
14. Wheeler TM, et al. (2009) Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 325:336-339.
15. Mulders SA, et al. (2009) Triplet-repeat oligonucleotidemediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci USA 106:13915-13920.
16. Mankodi A, et al. (2000) Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 289:1769-1773.
17. Gomes-Pereira M, Monckton DG (2006) Chemical modifiers of unstable expanded simple sequence repeats: What goes up, could come down. Mutat Res 598:15-34.
18. Wang GS, et al. (2009) PKC inhibition ameliorates the cardiac phenotype of a mouse model for myotonic dystrophy type 1. J Clin Invest, in press.